IndiaTickerLatest filing: Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome — recording
ObservedCompany dossier
Glenmark Pharmaceuticals
NSE:GLENMARK · ISIN INE935A01035
- Close
- Unavailable Date unavailable
- Daily change
- N/A Exchange close
- Evidence state
- Building 0/0 checks
Glenmark Pharmaceuticals
Overview
Evidence state
Coverage in progressCompany record at a glance
Latest reported period: 31 Mar 2026 · revenue ₹3,770.6 Cr · PAT ₹301.3 Cr.
Exchange XBRLLatest ownership: promoter group 46.65% and public 53.35% as of 30 Jun 2026.
Exchange XBRLMaterial events
Open timeline →What changed recently
Observed
Source filing Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome — recording
BSE · conference call recording
Observed
Source filing Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
BSE · conference call
Observed
Source filing Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Newspaper Publication
BSE · financial results
Observed
Source filing Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE · investor presentation
Reported financials
Full financials →31 Mar 2026
- Revenue from operations
- ₹3,770.6 Cr
- Profit after tax
- ₹301.3 Cr
- EPS
- ₹10.68
Observed BSE structured filing · consolidated
Ownership
Full shareholding →30 Jun 2026
- Promoter group
- 46.65%
- Public
- 53.35%
- Employee trust
- 0.00%
Observed NSE shareholding XBRL